Compounds > paxilline

Page last updated: 2024-08-26

paxilline and saracatinib

paxilline has been researched along with saracatinib in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	3 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Clack, G; Dixon, JM; Elvin, P; Fennell, M; Green, TP; Jacobs, V; Jones, RJ; Marshall, A; Renshaw, L; Womack, C; Young, O	1
Allen, J; Bermingham, A; Boyer, B; Carragher, N; Costello, GF; Curwen, J; Davies, BR; Elvin, P; Fennell, M; Green, TP; Hargreaves, J; Hennequin, LF; Hickinson, DM; Holdgate, GA; Jacobs, V; Logie, A; Plé, PA; Ward, WH; Whittaker, R; Wilkinson, RW	1
De Oliveira, E; Green, TP; Hidalgo, M; Jimeno, A; Messersmith, WA; Morgan, S; Rajeshkumar, NV; Tan, AC; Walker, J; Warren, MV; Womack, C; Wombwell, H	1

Other Studies

3 other study(ies) available for paxilline and saracatinib

Article	Year
Src inhibitors in early breast cancer: a methodology, feasibility and variability study. Breast cancer research and treatment, 2009, Volume: 114, Issue:2 Topics: Animals; Benzodioxoles; Breast Neoplasms; CSK Tyrosine-Protein Kinase; Feasibility Studies; Female; Focal Adhesion Kinase 1; Humans; Immunoenzyme Techniques; Lung Neoplasms; Paxillin; Phosphorylation; Protein-Tyrosine Kinases; Quinazolines; Rats; Rats, Nude; src-Family Kinases; Tumor Cells, Cultured; Xenograft Model Antitumor Assays	2009
Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530. Molecular oncology, 2009, Volume: 3, Issue:3 Topics: Administration, Oral; Animals; Antineoplastic Agents; Benzodioxoles; Cell Line, Tumor; Cell Movement; Cell Proliferation; Clinical Trials, Phase II as Topic; Focal Adhesion Kinase 1; Humans; Mice; Mice, Nude; Neoplasm Invasiveness; Neoplasm Proteins; Neoplasm Transplantation; NIH 3T3 Cells; Paxillin; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Rats; Rats, Nude; src-Family Kinases; Transplantation, Heterologous; Urinary Bladder Neoplasms; Xenograft Model Antitumor Assays	2009
Antitumor effects and biomarkers of activity of AZD0530, a Src inhibitor, in pancreatic cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 2009, Jun-15, Volume: 15, Issue:12 Topics: Animals; Antineoplastic Agents; Benzodioxoles; Biomarkers, Tumor; Female; Focal Adhesion Kinase 1; Gene Expression Profiling; Humans; Mice; Mice, Nude; Pancreatic Neoplasms; Paxillin; Proto-Oncogene Proteins pp60(c-src); Quinazolines; STAT3 Transcription Factor; Xenograft Model Antitumor Assays	2009